Current advantages in the application of proteomics in inflammatory bowel disease

Digestive Diseases and Sciences

Volumn 57, Issue 11, 2012, Pages 2755-2764

  Vaiopoulou, Anna ^a   Gazouli, Maria ^a   Theodoropoulos, George ^b   Zografos, George ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Crohn's disease; IBD; Proteomics; Ulcerative colitis

Indexed keywords

APOLIPOPROTEIN A4; APOLIPOPROTEIN C1; AUTOANTIBODY; C REACTIVE PROTEIN; CALGRANULIN; CALGRANULIN B; CELL ADHESION MOLECULE; CXCL16 CHEMOKINE; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EXOPEPTIDASE; FIBRINOGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTER ALPHA TRYPSIN INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12P40; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7; LACTOFERRIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; OROSOMUCOID; PEROXIREDOXIN 2; PLASMA PROTEIN; PROTEIN; PROTEOME; RESISTIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR CELL ADHESION MOLECULE 1;

AUTOIMMUNE DISEASE; COLON; CROHN DISEASE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE SEVERITY; EARLY DIAGNOSIS; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IRRITABLE COLON; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN MICROARRAY; PROTEIN PROCESSING; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; STAGING; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS; TWO DIMENSIONAL GEL ELECTROPHORESIS; ULCERATIVE COLITIS;

BIOLOGICAL MARKERS; HUMANS; INFLAMMATORY BOWEL DISEASES; PROGNOSIS; PROTEOMICS;

EID: 84871622044     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2291-4     Document Type: Review

References (94)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429.
2. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307-317.
3. Wirtz S, Neurath MF. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev. 2007;59:1073-1083.
4. Xavier R, Podolsky DK. Commensal flora: wolf in sheep's clothing. Gastroenterology. 2005;128:1122-1126.
5. Kugathasan S, Fiocchi C. Progress in basic inflammatory bowel disease research. Semin Pediatr Surg. 2007;16:146-153.
6. Meuwis MA, Fillet M, Geurts P, et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol. 2007;73:1422-1433.
7. Mendoza JL, Abreu MT. Biological markers in inflammatory bowel disease: practical consideration for clinicians. Gastroenterol Clin Biol. 2009;33:S158-S173.
8. Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Trans Res. 2012;159:313-325.
9. Li X, Conklin L, Alex P. New serological biomarkers of inflammatory bowel disease. World J Gastroenterol. 2008;14: 5115-5124.
10. Alex P, Gucek M, Li X. Applications of proteomics in the study of inflammatory bowel diseases: current status and future directions with available technologies. Inflamm Bowel Dis. 2009;15: 616-629.
11. Roy P, Shukla Y. Applications of proteomic techniques in cancer research. Cancer Therapy. 2008;6:841-856.
12. Goldknopf IL. Blood-based proteomics for personalized medicine: examples from neurodegenerative disease. Expert Rev Proteomics. 2008;5:1-8.
13. Veenstra TD, Conrads TP, Hood BL, Avellino AM, Ellenbogen RG, Morrison RS. Biomarkers: mining the biofluid proteome. Mol Cell Proteomics. 2005;4:409-418.
14. VanMeter A, Signore M, Pierobon M, Espina V, Liotta LA, Petricoin EF 3rd. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev Mol Diagn. 2007;7:625-633.
15. Cekaite L, Hovig E, Sioud M. Protein arrays: a versatile toolbox for target identification and monitoring of patient immune responses. Methods Mol Biol. 2007;360:335-348.
16. Hamelinck D, Zhou H, Li L, et al. Optimized normalization for antibody microarrays and application to serum-protein profiling. Mol Cell Proteomics. 2005;4:773-784.
17. Chaerkady R, Pandey A. Applications of proteomics to lab diagnosis. Annu Rev Pathol. 2008;3:485-498.
18. Cravatt BF, Simon GM, Yates JR 3rd. The biological impact of mass-spectrometry-based proteomics. Nature. 2007;450:991-1000.
19. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature. 2008;452:571-579.
20. Gulcicek EE, Colangelo CM, McMurray W, et al. Proteomics and the analysis of proteomic data: an overview of current proteinprofiling technologies. Curr Protoc Bioinformatics. 2005;13:1.
21. Reinders J, Sickmann A. Modificomics: posttranslational modifications beyond protein phosphorylation and glycosylation. Biomol Eng. 2007;24:169-177.
22. Walsh CT, Garneau-Tsodikova S, Gatto GJ Jr. Protein posttranslational modifications: the chemistry of proteome diversifications. Angew Chem Int Ed Engl. 2005;44:7342-7372.
23. Felley-Bosco E, André M. Proteomics and chronic inflammatory bowel diseases. Pathol Res Pract. 2004;200:129-133.
24. Feng JT, Shang S, Beretta L. Proteomics for the early detection and treatment of hepatocellular carcinoma. Oncogene. 2006;25: 3810-3817.
25. Mann M, Hendrickson RC, Pandey A. Analysis of proteins and proteomes by mass spectrometry. Annu Rev Biochem. 2001; 70:437-473.
26. Hatsugai M, Kurokawa MS, Kouro T, et al. Protein profiles of peripheral blood mononuclear cells are useful for differential diagnosis of ulcerative colitis and Crohn's disease. J Gastroenterol. 2010;45:488-500.
27. Markó L, Szigeti N, Szabó Z, et al. Potential urinary biomarkers of disease activity in Crohn's disease. Scand J Gastroenterol. 2010;45:1440-1448.
28. Meuwis MA, Fillet M, Lutteri L, et al. Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study. Clin Biochem. 2008;41:960-967.
29. Nanni P, Parisi D, Roda G, et al. Serum protein profiling in patients with inflammatory bowel diseases using selective solidphase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis. Rapid Commun Mass Spectrom. 2007;21:4142-4148.
30. Subramanian V, Subramanian D, Pollok RC. Serum protein signatures determined by mass Spectrometry (SELDI-ToF) accurately distinguishes Crohn's disease (CD) from ulcerative colitis (UC). Gastroenterology. 2008;134:196.
31. Bertone P, Snyder M. Advances in functional protein microarray technology. FEBS J. 2005;272:5400-5411.
32. Hall David A, Ptacek Jason, Snyder Michael. Protein microarray technology. Mech Ageing Dev. 2007;128:161-167.
33. Chen CS, Sullivan S, Anderson T, et al. Identification of novel serological biomarkers for inflammatory bowel disease using Escherichia coli proteome chip. Mol Cell Proteomics. 2009;8: 1765-1776.
34. Vermeulen N, Vermeire S, Michiels G, Joossens M, Rutgeerts PJ, Bosuyt X. Protein microarray experiments for profiling of the autoimmune response in inflammatory bowel disease; identification of PHLA1. Gastroenterology. 2008;134:197.
35. Sullivan S, Zhu H, Cuffari C, et al. Identification and validation of serological IBD biomarkers by a novel high throughput proteomic approach using high density protein chip technology. Gastroenterology. 2006;130:A24.
36. Kader HA, Tchernev VT, Satyaraj E, et al. Patel. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-b1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol. 2005;100:414-423.
37. Schrader M, Schulz-Knappe P. Peptidomics technologies for human body fluids. Trends Biotechnol. 2001;19:S55-S60.
38. Govorun VM, Ivanov VT. Proteomics and peptidomics in fundamental and applied medical studies. Bioorg Khim. 2011;37: 199-215.
39. Nanni P, Levander F, Roda G, Caponi A, James P, Roda A. A label-free nano-liquid chromatography-mass spectrometry approach for quantitative serum peptidomics in Crohn's disease patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:3127-3136.
40. Ray S, Reddy PJ, Jain R, Gollapalli K, Moiyadi A, Srivastava S. Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics. 2011;11:2139-2161.
41. Dotan I. New serologic markers for inflammatory bowel disease diagnosis. Dig Dis. 2010;28:418-423.
42. Hu S, Loo JA, Wong DT. Human body fluid proteome analysis. Proteomics. 2006;6:6326-6353.
43. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature. 2003;425:905.
44. Haleem JI, Zhen X, Timothy DV. Serum and plasma proteomics. Chem Rev. 2007;107:3601-3620.
45. Ebert MP, Korc M, Malfertheiner P, Rocken C. Advances, challenges, and limitations in serum-proteomebased cancer diagnosis. J Proteome Res. 2006;5:19-25.
46. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem. 2006;52:171-181.
47. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001;96:730-734.
48. Dubinsky MC, Lin YC, Dutridge D, et al. Western Regional Pediatric IBD Research Alliance. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101:360-367.
49. Dotan I, Fishman S, Dgani Y, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology. 2006;131:366-378.
50. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007;56:1394-1403.
51. Vandewalle-El Khoury P, Colombel JF, Joossens S, et al. Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and prediction. Am J Gastroenterol. 2008;103:949-957.
52. Sakiyama T, Fujita H, Tsubouchi H. Autoantibodies against ubiquitination factor E4A (UBE4A) are associated with severity of Crohn's disease. Inflamm Bowel Dis. 2008;14:310-317.
53. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661-665.
54. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11: 707-712.
55. Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol. 1988;10:401-405.
56. Wright JP, Young GO, Tigler-Wybrandi N. Predictors of acute relapse of Crohn's disease. A laboratory and clinical study. Dig Dis Sci. 1987;32:164-170.
57. Sachar DB, Smith H, Chan S, Cohen LB, Lichtiger S, Messer J. Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease. J Clin Gastroenterol. 1986;8: 647-650.
58. Sachar DB, Luppescu NE, Bodian C, Shlien RD, Fabry TL, Gumaste VV. Erythrocyte sedimentation as a measure of Crohn's disease activity: opposite trends in ileitis versus colitis. J Clin Gastroenterol. 1990;12:643-646.
59. Jensen KB, Jarnum S, Koudahl G, Kristensen M. Serum orosomucoid in ulcerative colitis: its relation to clinical activity, protein loss, and turnover of albumin and IgG. Scand J Gastroenterol. 1976;11:177-183.
60. Andre C, Descos L, Landais P, Fermanian J. Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. Gut. 1981;22:571-574.
61. Lehrke M, Konrad A, Schachinger V, et al. CXCL16 is a surrogate marker of inflammatory bowel disease. Scand J Gastroenterol. 2008;43:283-288.
62. Broedl UC, Schachinger V, Lingenhel A, et al. Apolipoprotein A-IV is an independent predictor of disease activity in patients with inflammatory bowel disease. Inflamm Bowel Di. 2007;13:391-397.
63. Konrad A, Lehrke M, Schachinger V, et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol. 2007;19:1070-1074.
64. Van Assche G, Rutgeerts P. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2005;288:G169-G174.
65. Magro F, Araujo F, Pereira P, Meireles E, Diniz-Ribeiro M, Velosom FT. Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease. Dig Dis Sci. 2004;49:1265-1274.
66. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-135.
67. Stronkhorst A, Jansen J, Tytgat G, van Deventer SJH. Soluble IL-2 and TNF receptors p55 and p75 in Crohn's disease. Gastroenterology. 1994;106:A779.
68. Propst A, Propst T, Herold M, Vogel W, Judmaier G. Interleukin-1 receptor antagonist in differential diagnosis of inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 1995;7:1031-1036.
69. Casini-Raggi V, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol. 1995;154:2434-2440.
70. Crabtree JE, Juby LD, Heatley RV, Lobo AJ, Bullimore DW, Axon AT. Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity. Gut. 1990;31:1033-1036.
71. Nielsen OH, Brynskov J. Soluble interleukin-2 receptors in ulcerative colitis. Mediators Inflamm. 1993;2:115-118.
72. Gustot T, Lemmers A, Louis E, et al. Profile of soluble cytokine receptors in Crohn's disease. Gut. 2005;54:488-495.
73. Jones SC, Evans SW, Lobo AJ, Ceska M, Axon AT, Whicher JT. Serum interleukin-8 in inflammatory bowel disease. J Gastroenterol Hepatol. 1993;8:508-512.
74. Kucharzik T, Stoll R, Lügering N, Domschke W. Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol. 1995;100:452-456.
75. Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol. 2001;7:460-465.
76. Angriman I, Scarpa M, D'Incà R, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta. 2007;381:63-68.
77. Poullis A, Foster R, Northfield TC, Mendal MA. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:675-681.
78. Saverymuttu SH, Peters AM, Crofton ME, et al. 111Indium autologous granulocytes in the detection of inflammatory bowel disease. Gut. 1985;26:955-960.
79. Fagerhol MK, Dale I, Anderson I. Release and quantification of leukocyte derived protein (L1). Scand J Haematol. 1980;24: 393-398.
80. Taehon K, Roseth AG, Foster R, Bjarnason I. Fecal calprotectin: a simple sensitive quantitative measure of intestinal inflammation in man. Gastroenterology. 1997;112:A1103.
81. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterolgy. 2000;119:15-22.
82. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005;54:364-368.
83. Gisbert JP, Bermejo F, Pérez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009;15:1190-1198.
84. Walker TR, Land ML, Kartashov A, et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:414-422.
85. Foell D, Kucharzik T, Kraft M, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut. 2003;52:847-853.
86. Hugot J-P, Chamaiilard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603.
87. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in Nod2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-606.
88. Franke A, McGovern DP, Barrett JC, et al. Genome-wide metaanalysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genet. 2010;42:1118-1125.
89. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genet. 2011;43:246-252.
90. Mascheretti S, Hampe J, Croucher PJ, et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics. 2002;12:509-515.
91. Mascheretti S, Schreiber S. Genetic testing in Crohn disease: utility in individualizing patient management. Am J Pharmacogenomics. 2005;5:213-222.
92. Beaven SW, Abreu MT. Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol. 2004;20:318-327.
93. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
94. Summerton CB, Longlands MG, Wiener K, Shreeve DR. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002;14:841-845.